Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

SynBioBeta SF 2016

I had the chance to attend the SynBioBeta conference in October, where I was able to observe the impressive strides the field has made over the past year. I wrote an article concerning my takeaways for investors and entrepreneurs, which was posted on the SynBioBeta website. It can be viewed here.

Synthetic Biology at IndieBio Demo Day 4

Modernizing the Regulatory System for Biotechnology Products